- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03133650
A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing
May 23, 2023 updated by: Memorial Sloan Kettering Cancer Center
A Phase I Trial of Vascular-Targeted Photodynamic Therapy in Esophagogastric Cancer Patients With Moderate to Severe Dysphagia
The purpose of this study is to establish the highest dose of laser light for WST-11 VTP to treat obstruction from esophageal cancer that can be safely given.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Reẖovot, Israel
- Weizmann Institute of Science
-
-
-
-
New York
-
New York, New York, United States, 10021
- Memorial Sloan - Kettering Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 18 or older
- Confirmed tissue diagnosis of esophageal squamous cell cancer, adenocarcinoma or poorly differentiated carcinoma, with pathology reviewed at MSKCC
Has incurable disease defined as at least one of the following:
- Presence of metastases to other organs (Stage IV), now or previously
- Has locally advanced disease and are not candidates for surgery or more radiation treatment
- Has received the maximal radiation therapy to the primary site, or has been assessed by radiation oncology as not being a candidate for chemoradiation therapy.
- Karnofsky performance status >/= 50%
- No endoluminal stent in place at the time of treatment
- Previous esophageal dilation is permitted, provided the patient has developed recurrent dysphagia since that procedure
- Patients should not have received any systemic therapy (including chemotherapy, biologic therapy or immunotherapy) </= 7 days prior to treatment
- Prior radiation or surgery to the esophagus is permitted for patients with locally recurrent/persistent disease
- Patients on prophylactic or full-dose anticoagulation are eligible, provided the treating physician believes it is safe to temporarily withhold anticoagulation (see Section 9.2)
Adequate organ function defined at baseline as:
- ANC ≥1,000/ L
- Platelets ≥75,000/ L
- Hb ≥8.5 g/dl
- INR ≤1.5 (except for patients who are on full-dose warfarin)
- Calculated creatinine clearance ≥50 ml/min (using Cockcroft-Gault method)
- Total serum bilirubin ≤1.5 mg/dL, or </= 2.5 mg/dL for patients with a known history of Gilbert's syndrome
- AST/ALT ≤5× upper limit of normal
- Able to provide written informed consent
Exclusion Criteria:
Pregnant or breast-feeding women. Women of childbearing potential (WOCBP) must undergo a negative pregnancy test (either serum or urine) prior to study entry. Both sexes must use contraception while on study. WOCBP include:
- Any woman who has experienced menarche and who has not undergone surgical sterilization (hysterectomy, bilateral tubal ligation or oophorectomy) or who is not post-menopausal (defined as amenorrheic ≥12 consecutive months)
- Women on hormone replacement therapy with documented serum follicle stimulating hormone level > 35 mIU/ml
- Women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as intrauterine device or barrier methods to prevent pregnancy or are practicing abstinence of where the partner is sterile
- T4 tumors with involvement of any adjacent structure, including the trachea, aorta or pleura
- Prior history of esophageal perforation
- Any other medical or psychiatric comorbidities, including decompensated heart failure, unstable angina or coronary artery disease or severe pulmonary disease, that, in the opinion of the study investigator, would make the patient a poor candidate for the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vascular-targeted photodynamic therapy (VTP) using WST11
Participants will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes, during an endoscopy procedure, followed by immediate laser light application.
|
Administration of WST11 in conjunction with endoscopic illumination at 753 nm emitted by a diode laser and administered to the participant by optical fibre catheters (cylindrical light diffusers) and a standard upper GI endoscope.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated laser fluence rate
Time Frame: 60 days
|
The maximally tolerated laser light fluence rate (mW/cm) of light exposure for VTP of malignant obstruction due to esophagogastric cancer will be measured by examining 6 fluence rates beginning with a fluence rate of 150 nW/cm, then increasing by 50mW/cm, up to a maximum of 400 mW/cm (150, 200, 250 300, 350, 400).
|
60 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Hans Gerdes, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 26, 2017
Primary Completion (Anticipated)
February 23, 2025
Study Completion (Anticipated)
February 23, 2025
Study Registration Dates
First Submitted
April 26, 2017
First Submitted That Met QC Criteria
April 26, 2017
First Posted (Actual)
April 28, 2017
Study Record Updates
Last Update Posted (Actual)
May 24, 2023
Last Update Submitted That Met QC Criteria
May 23, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-319
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophagogastric Cancer
-
University Health Network, TorontoRecruiting
-
Massachusetts General HospitalDana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Synta Pharmaceuticals...CompletedEsophagogastric CancerUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedEsophagogastric CancerUnited States
-
Washington University School of MedicineGateway for Cancer ResearchWithdrawnEsophagogastric Cancer
-
Memorial Sloan Kettering Cancer CenterJanssen PharmaceuticalsRecruiting
-
SCRI Development Innovations, LLCGlaxoSmithKlineTerminatedHER2 Positive Esophagogastric CancerUnited States
-
Zhonglin HaoUniversity of Kentucky; BeiGeneWithdrawnEsophageal Cancer | Esophagogastric Junction CancerUnited States
-
Memorial Sloan Kettering Cancer CenterBristol-Myers Squibb; BayerActive, not recruitingEsophagogastric Cancer | HER2-NegativeUnited States
-
St. James's Hospital, IrelandUnknownBarrett Esophagus | Siewert Type II Adenocarcinoma of Esophagogastric Junction | Oesophagus Cancer | Siewert Type I Adenocarcinoma of Esophagogastric Junction | Siewert Type III Adenocarcinoma of Esophagogastric JunctionIreland
-
P. Herzen Moscow Oncology Research InstituteNational Medical Research Radiological Centre of the Ministry of Health of...Not yet recruitingEsophageal Cancer | Oesophageal Cancer | Siewert Type I Adenocarcinoma of Esophagogastric Junction | Siewert Type III Adenocarcinoma of Esophagogastric JunctionRussian Federation
Clinical Trials on WST 11-mediated VTP therapy
-
Steba Biotech S.A.CompletedProstate CancerUnited States
-
Steba Biotech S.A.TerminatedCholangiocarcinomaFrance
-
Steba Biotech S.A.CompletedProstate CancerFrance, United Kingdom, Canada
-
Steba Biotech S.A.TerminatedNon-Small Cell Lung CancerFrance
-
Steba Biotech S.A.CompletedProstate CancerNetherlands, France, United Kingdom
-
Impact Biotech LtdImpact biotech Ltd.Not yet recruitingLocally Advanced Unresectable Pancreatic Adenocarcinoma
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingUpper Tract Urothelial CarcinomaUnited States
-
Impact Biotech LtdImpact biotech Ltd.Not yet recruitingPeripheral Lung Tumor
-
University of Dublin, Trinity CollegeFoundation for Medical Research; Friends of the Royal Hospital DonnybrookUnknownBalance | WeaknessIreland
-
Changi General HospitalNot yet recruitingStroke, Acute